Hsbc Holdings PLC Cure Vac N.V. Transaction History

Hsbc Holdings PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $223,824 - $456,026	-29,923 Reduced 36.1%	52,961 $418,000
Q2 2022 Aug 11, 2022	BUY	$13.18 - $19.41 $1.06 Million - $1.56 Million	80,164 Added 2947.21%	82,884 $1.12 Million
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $32,700 - $78,255	2,220 Added 444.0%	2,720 $53,000
Q4 2021 Feb 11, 2022	SELL	$33.72 - $48.22 $888,016 - $1.27 Million	-26,335 Reduced 98.14%	500 $17,000
Q3 2021 Nov 12, 2021	BUY	$49.26 - $74.5 $1.16 Million - $1.75 Million	23,501 Added 704.89%	26,835 $1.48 Million
Q2 2021 Aug 13, 2021	BUY	$56.91 - $127.53 $144,266 - $323,288	2,535 Added 317.27%	3,334 $244,000
Q1 2021 May 14, 2021	BUY	$79.79 - $126.29 $63,752 - $100,905	799 New	799 $73,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $514M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.